stoxline Quote Chart Rank Option Currency Glossary
  
Reneo Pharmaceuticals, Inc. (RPHM)
1.61  -0.02 (-1.23%)    02-23 16:00
Open: 1.61
High: 1.655
Volume: 379,885
  
Pre. Close: 1.63
Low: 1.61
Market Cap: 54(M)
Technical analysis
2024-02-23 4:39:14 PM
Short term     
Mid term     
Targets 6-month :  2.16 1-year :  2.52
Resists First :  1.85 Second :  2.16
Pivot price 1.64
Supports First :  1.52 Second :  1.32
MAs MA(5) :  1.62 MA(20) :  1.65
MA(100) :  4.53 MA(250) :  6.01
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  17.8 D(3) :  19.5
RSI RSI(14): 34.5
52-week High :  11.29 Low :  0.98
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RPHM ] has closed above bottom band by 21.3%. Bollinger Bands are 93.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.66 - 1.67 1.67 - 1.68
Low: 1.58 - 1.59 1.59 - 1.61
Close: 1.59 - 1.61 1.61 - 1.63
Company Description

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Headline News

Sat, 24 Feb 2024
Reneo Pharmaceuticals (NASDAQ:RPHM) Trading Down 1.2% - MarketBeat

Wed, 27 Dec 2023
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednes - Benzinga

Wed, 27 Dec 2023
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In ... - Markets Insider

Mon, 25 Dec 2023
Concentra Biosciences, LLC submitted a non-binding proposal to acquire Reneo Pharmaceuticals, Inc. for $60 million. - Marketscreener.com

Fri, 15 Dec 2023
Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study - Zacks Investment Research

Thu, 14 Dec 2023
Reneo stock plunges 84% as company shuts down lead program (NASDAQ:RPHM) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 33 (M)
Shares Float 15 (M)
Held by Insiders 3 (%)
Held by Institutions 82.4 (%)
Shares Short 1,630 (K)
Shares Short P.Month 1,750 (K)
Stock Financials
EPS -2.36
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.39
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -35.9 %
Return on Equity (ttm) -59.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.18
Qtrly Earnings Growth 0 %
Operating Cash Flow -60 (M)
Levered Free Cash Flow -35 (M)
Stock Valuations
PE Ratio -0.69
PEG Ratio 0
Price to Book value 0.47
Price to Sales 0
Price to Cash Flow -0.91
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android